Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Melanoma (Skin Cancer), Hepatocellular C...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, or cholangiocarcinoma will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 68Ga-SorB PET/CT — Participants will receive a single intravenous administration of 68Ga-SorB (approximately 3.7 MBq/kg), followed by whole-body PET/CT imaging approximately 60 minutes after injection. The imaging findings will be compared with clinically indicated 18F-FDG PET/CT and reference standard findings to evaluate the safety, feasibility, biodistribution, tumor uptake, and exploratory diagnostic performance of 68Ga-SorB PET/CT.

Primary Outcomes

  • Incidence of adverse events related to 68Ga-SorB PET/CT (From tracer administration until completion of the imaging visit (approximately 24 hours).)
  • Successful completion of 68Ga-SorB PET/CT imaging (At completion of PET/CT imaging (approximately 60 minutes after tracer injection))
  • Tumor uptake of 68Ga-SorB measured by SUVmax (At PET/CT imaging (approximately 60 minutes after tracer injection))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-13
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University Third Hospital
Contact Information
Study Contact:
Meixin Zhao
86-10-82264936
zhaomeixin.student@sina.com
Meixin Zhao
86-10-82264936
zhaomeixin.student@sina.com
Peking University Third Hospital
Interventions
  • Diagnostic Test: 68Ga-SorB PET/CT — Participants will receive a single intravenous administration of 68Ga-SorB (approximately 3.7 MBq/kg), followed by whole-body PET/CT imaging approximately 60 minutes after injection. The imaging findings will be compared with clinically indicated 18F-FDG PET/CT and reference standard findings to evaluate the safety, feasibility, biodistribution, tumor uptake, and exploratory diagnostic performance of 68Ga-SorB PET/CT.
Study Locations (1 sites)
Peking University Third Hospital, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 or older. * Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, ovarian cancer, or cholangiocarcinoma. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic, hepatic, renal, and coagulation function: * White blood cell count ≥ 4.0 × 10\^9/L or absolute neutrophil count ≥ 1.5 × 10\^9/L; * Platelet count ≥ 100 × 10\^9/L; * Hemoglobin ≥ 90 g/L; * PT or APTT ≤ 1.5 × upper limit of normal (ULN); * Total bilirubin ≤ 1.5 × ULN; * ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases); * ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases); * Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN. * Normal cardiac function. * Estimated life expectancy of at least 12 weeks. * Willing and able to comply with study procedures and follow-up. * At least one measurable target lesion according to RECIST version 1.1. * Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET/CT imaging. * Clinically indicated to undergo 18F-FDG PET/CT for tumor evaluation. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate. * Inability to tolerate PET/CT imaging or complete study follow-up. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Conditions Diabetes Mellitus, Type 2, Diabetes Educ...
Phase NA
Enrollment 65
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the use and effectiveness of a mobile web application (app) that is designed to educate and allow patients to manage diabetes and make sustainable lifestyle changes, and to study the impact of the app on clinical outcomes of diabetes (HA1C) and educational outcomes (Self-Efficacy for Diabetes Scale). The main question to answer is: Does the use of the Diabetes Application significantly affect clinical outcomes of diabetes and cardiometabolic risk factors (BMI and Blood Pressure)? Patients will be enrolled in one of two available arms of the study. Participants in the 'intervention arm' will use the app to view educational information presented as videos in the following areas: Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes and Disease Pathophysiology. They will continue routine follow-up care with their primary care physicians during the study. Participants in the 'control arm' will continue with their primary care physician in routine follow-up care, as normally scheduled. Researchers will compare the intervention arm participants to the control arm participants to find out about and compare changes in HA1C, systolic blood pressure, diastolic blood pressure, and body mass index. Groups will also be compared on the basis of self-perceived confidence of managing their diabetes by way of the Diabetes Self Efficacy Scale.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Diabetes education web site application — The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.

Primary Outcomes

  • Hemoglobin A1c (6 months)
  • "Self-Efficacy for Diabetes Scale" (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-15
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Reading Hospital and Medical Center
Collaborators: Reading Hospital Foundation, Complete Statistical Services (Consult-Stat)
Principal Investigators:
  • Luis A Murillo, MD, MPH (PRINCIPAL_INVESTIGATOR) - Reading Hospital Tower Health
Contact Information
Study Contact:
Mary E Alderfer, MSN
484-628-8360
mary.alderfer@towerhealth.org
Pamela Marrero
484-628-8355
pamela.marrero@towerhealth.org
Research coordinator
484-628-8585
research@towerhealth.org
Reading Hospital, an affiliate of Tower Health
Interventions
  • Other: Diabetes education web site application — The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
Study Locations (1 sites)
Reading Hospital, an affiliate of Tower Health, West Reading, Pennsylvania 19611 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of Type 2 Diabetes with HA1c \>8.0 * Current patients of the Family Healthcare Center, Reading Hospital Tower health. Exclusion Criteria: * Identified special populations (pregnancy or individuals currently incarcerated) * Patients without access to their own smart phone * Any patient who is unable to provide their own informed consent to participate in the study
Conditions Diabetes Mellitus, Type 2, Obesity, Pred...
Phase NA
Enrollment 123
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Early (7:00 - 16:00) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
  • Behavioral: Mid (9:30 - 18:30) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
  • Behavioral: Late (12:00 - 21:00) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.

Primary Outcomes

  • Average 24-hour glucose total area under the curve (AUC) over 7 days (7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-28
Completion: 2027-06-28
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 123 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Toronto
Collaborators: Diabetes Canada, Wharton Medical Clinic
Principal Investigators:
  • Amy A. Kirkham, PhD (PRINCIPAL_INVESTIGATOR) - University of Toronto
Contact Information
Study Contact:
Amy A Kirkham, PhD
416-946-4069
amy.kirkham@utoronto.ca
Teresita Gormaz Clinical Trial coordinator, MsC
+1-416-946-0036
establish.study.kpe@utoronto.ca
Amy A Kirkham, PhD
Remote Ontario-wide
Interventions
  • Behavioral: Early (7:00 - 16:00) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
  • Behavioral: Mid (9:30 - 18:30) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
  • Behavioral: Late (12:00 - 21:00) TRE — A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
Study Locations (1 sites)
Remote Ontario-wide, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * Aged 40 years or older * Body mass index \<50 kg/m2 * Have access to an Apple or Android cellphone with Bluetooth. * Have type 2 diabetes or be at risk for type 2 diabetes (defined as self-report of pre-diabetes, a recent (within 12 months) measure of HbA1c between 5.7 and 6.4%, waist circumference (WC) that is BMI specific; for women: BMI \>= 18.5-24.9, WC \>= 80cm; BMI \>= 25-29.9, WC \>= 90cm; BMI \>= 30-34.9, WC \>= 105cm; BMI \>= 35+, WC \>= 115cm; for men: BMI \>= 18.5-24.9, WC \>= 90cm; BMI \>= 25-29.9, WC \>= 100cm; BMI \>= 30-34.9, WC \>= 110cm; BMI \>= 35+, WC \>= 125cm. Exclusion Criteria: * Individuals with type 2 diabetes will be excluded if: (1) currently on \>2 monotherapies for diabetes, (2) have had diabetes therapy medication or dosage changes \<3 months, (3) self-reported hemoglobin A1c \>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas * The following exclusion criteria applies to all potential participants: 1. History of or referral for bariatric surgery 2. Weight loss \>3% in the last 3 months 3. Taking antiobesity (weight loss) medications 4. Body weight \>390lbs 5. Diagnosed with severe cognitive disorder that precludes them from giving consent 6. Inability or unwillingness to change their eating window to follow those prescribed in the study 7. Currently consistently eating during \<11.5 hour period . 8. Physician-diagnosed eating disorder 9. Having a pacemaker or receiving dialysis. 10. Not having access to a Lifelabs location.
Conditions Type 2 Diabetes, Hepatic Steatosis
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Magnetic Resonance Liver Assessment — Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
  • Other: Bike Exercise VO2max — Maximal fitness measured by cycle ergometer.
  • Other: DEXA — Measure body composition (fat and lean body mass).

Primary Outcomes

  • Measurement of Endogenous Glucose Production (EGP) (Day 14)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-25
Completion: 2028-12
Eligibility
Age: 25 Years – 55 Years
Sex: ALL
Volunteers: true
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AdventHealth Translational Research Institute
Principal Investigators:
  • Justine Mucinski, PhD (PRINCIPAL_INVESTIGATOR) - AdventHealth
Contact Information
Study Contact:
Recruitment Department
407-303-7100
CFD.TRI.Recruitment@AdventHealth.com
Recruitment Department
407-303-7100
CFD.TRI.Recruitment@AdventHealth.com
AdventHealth Translational Research Institute
Interventions
  • Other: Magnetic Resonance Liver Assessment — Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
  • Other: Bike Exercise VO2max — Maximal fitness measured by cycle ergometer.
  • Other: DEXA — Measure body composition (fat and lean body mass).
Study Locations (1 sites)
AdventHealth Translational Research Institute, Orlando, Florida 32804 United States
Eligibility Criteria
Inclusion criteria for individuals with T2D and elevated liver fat ≥5.6% 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 25 and 45 kg/m2 5. Sedentary (1 day or less per week of structured exercise) 6. Type 2 diabetes mellitus: HbA1c ≥7.5% 7. Liver fat ≥5.6% based on MRI 8. Weight stable (± 2 kg) for prior 3 months Inclusion criteria for lean, healthy controls 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 18.5 and 27.5 kg/m2 5. Normal liver fat (FibroScan CAP \<249dB/m, \<5.6% liver fat based on MRI) 6. Weight stable (± 2 kg) for prior 3 months 7. Active (≥3 day/week of structured exercise) Exclusion Criteria 1. Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and/or thiazolidinediones 2. Any change in glucose-lowering medications within the previous three months. 3. Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7. 4. Resting blood pressure ≥ 160/100 mm Hg 5. Triglycerides ≥ 500 mg/dL 6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol 7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months 11. Post- or peri-menopausal women 12. Partial and/or full hysterectomy (self-report) 13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting 15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 16. New onset (\<3 months on a stable regime) hormone replacement therapy 17. Current use of beta-adrenergic blocking agents 18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 19. Previous bariatric or other surgery for obesity 20. Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months 21. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 22. Current drug or alcohol abuse/dependence, or positive urine toxicology screen 23. Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month) 24. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening 25. Not physically capable of performing the exercise required of the study protocols 26. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 27. Unable to tolerate MRI or claustrophobia. 28. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year 29. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy 30. Unable or unwilling to communicate with staff or to provide written informed consent Exclusion criteria for lean, healthy controls 1. Currently taking insulin, injectable incretin mimetics, and/or thiazolidinediones 2. Taking glucose-lowering medications 3. HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes 4. Resting blood pressure ≥ 160/100 mm Hg 5. Triglycerides ≥ 500 mg/dL 6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol 7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year 11. Post- or peri-menopausal women 12. Partial and/or full hysterectomy (self-report) 13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting 15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 16. New onset (\<3 months on a stable regime) hormone replacement therapy 17. Current use of beta-adrenergic blocking agents 18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 19. Previous bariatric or other surgery for obesity 20. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal) 21. Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months 22. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 23. Current drug or alcohol abuse/dependence, or positive urine toxicology screen 24. Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month) 25. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening 26. Not physically capable of performing the exercise required of the study protocols 27. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 28. Unable to tolerate MRI or claustrophobia. 29. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year 30. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy 31. Unable or unwilling to communicate with staff or to provide written informed consent
Conditions Diabete Mellitus, T2 Diabetes and Fatty ...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: pulsENDO treatment — The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.

Primary Outcomes

  • HbA1c ≤6.5% without glucose lowering drugs (6 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2032-08-30
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Stephen Ng, FRCSEd(Gen) (PRINCIPAL_INVESTIGATOR) - Prince of Wales Hospital, the Chinese University of Hong Kong
Contact Information
Study Contact:
Stephen Ng, FRCSEd(Gen)
+85235052956
stephenng@surgery.cuhk.edu.hk
Stephen Ng, FRCSEd(Gen)
+85235052956
stephenng@surgery.cuhk.edu.hk
Chinese University of Hong Kong
Jenny Ho
+85235052956
jennyho@surgery.cuhk.edu.hk
Chinese University of Hong Kong
Interventions
  • Procedure: pulsENDO treatment — The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.
Study Locations (1 sites)
Chinese University of Hong Kong, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Duration of T2DM \</= 2 years * HbA1c \</= 7.5% * On 0-1 oral diabetes medications Exclusion Criteria: * Previous treatment with pulsENDO or similar procedure * Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO * Type I DM, DM secondary to specific disease or having any history of ketoacidosis * Fasting C-peptide level \<0.5ug/L * Any inflammatory disease of the gastrointestinal tract such as Crohn's disease * Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study * Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy * Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and/or there is a need or expected need to use during the study period * Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) * Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month * Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder. * Patients with contra-indications to endoscopy * Malignancy * Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma) * Pregnant or breast feeding * ASA grade IV \& V * Mental or psychiatric disorder; Drug or alcohol addiction * Other cases deemed by the examining physician as unsuitable for safe treatment * Refusal to participate
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective study is to evaluate diabetes outcomes and patient experience following a switch from second generation intermittently scanned continuous glucose monitor (isCGM) to real-time continuous glucose monitor (rtCGM) compared with participants with continued isCGM use among adults with insulin-treated type 2 diabetes (T2D) in a specialist endocrinology clinic setting in Canada. The study aims include: Primary outcome - Evaluate change in percent time in range (TIR) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with participants with continued second generation isCGM use. Secondary outcomes - Compare glycemic and metabolic outcomes (ie. additional CGM metrics, HbA1c, and weight), and outcomes related to diabetes management (ie. self-reported hypoglycemia and change in total daily dose \[TDD\] of insulin) at 3-6 months follow-up in the rtCGM switch and isCGM cohorts among adults with insulin-treated T2D. Exploratory outcomes - Evaluate patient-reported outcomes (PROs) in the rtCGM switch cohort only. PROs will include questions about device satisfaction and psychological distress at baseline and 3-6 months follow-up, and protocol-specific questions about Dexcom Care following use of the rtCGM device at 3-6 months follow-up. Additionally this study will compare percent TIR, percent TBR, percent TAR, and HbA1c between rtCGM switch and isCGM cohorts by insulin therapy subgroup (basal vs MDI therapy). rtCGM switch participants will be enrolled at an LMC location and asked to complete PROs at baseline and 3-6 month follow-up. Continued isCGM participants will not be asked to complete PROs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: real-time continuous glucose monitor — Individuals who switched from using isCGM to rtCGM

Primary Outcomes

  • Change in Percent Time in Range (TIR) (from enrollment to 6 months follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-11
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LMC Diabetes & Endocrinology Ltd.
Collaborators: DexCom, Inc.
Contact Information
Study Contact:
Manager, Data Science, LMC Healthcare
4166452929
lisa.chu@lmc.ca
LMC Diabetes & Endocrinology Ltd.
Research Assistant, Data Science, LMC Healthcare
giovana.romero@lmc.ca
LMC Diabetes & Endocrinology Ltd.
Interventions
  • Device: real-time continuous glucose monitor — Individuals who switched from using isCGM to rtCGM
Study Locations (1 sites)
LMC Diabetes & Endocrinology Ltd., Toronto, Ontario M4G 3E8 Canada
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Clinical diagnosis of T2D ≥ one year * Using insulin for ≥ 6 months * Continued FreeStyle Libre® 2 isCGM device (isCGM cohort) as of the study start date * Would like to switch from a FreeStyle Libre® 2 isCGM device to a Dexcom® G7 rtCGM device (rtCGM switch cohort) as of the study start date * Baseline HbA1c ≥ 7.5% * Known rtCGM/isCGM start date (month and year) * Exclusive use of isCGM for ≥ 3 months * Data on LibreView platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date * ≥ 1 value for TIR (%) up to 6 months (± 6 weeks) prior to index date * ≥ 1 value for HbA1c (%) up to 6 months (± 6 weeks) prior to index date * Data consent Exclusion Criteria: * Have a prior history of rtCGM within 12 months of the index date * Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date * Recent or expectant titration of insulin dose ≥ 20% within 30 days of index date * Are pregnant at the time of study enrollment or intending to become pregnant during the study * Used the isCGM or rtCGM for \< 3 months * Using continuous subcutaneous insulin infusion
Conditions Type 2 Diabetes, Insulin Sensitivity/Res...
Phase PHASE2, PHASE3
Enrollment 60
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

About 6.5 million adults in the United States who are 65 or older have dementia. While the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Intranasal Insulin — Dosage will be 20 IU of INI twice per day (40 IU in total/day). The study will use the Kurve Technology intranasal device, which delivers a 20 second stream of insulin through a nose piece into a nostril, after which the device switches off. The process will then be repeated in the other nostril.
  • Drug: Intranasal Placebo — Saline will be administered twice daily (20 seconds in each nostril) using the Kurve Technology intranasal insulin device.
  • Behavioral: High Intensity Exercise — High intensity exercise will consist of 16 weeks of walking at \~85% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk. The duration of each exercise session will be adjusted based on fitness level so that \~300 kcal will be expended per training session during weeks 1-2, 350 kcal per training session during weeks 3-4, and 400 kcal per training session during weeks 5-16. This usually equals \~60 minutes per session but can vary from person to person. Each session will start with a 5-minute warm-up and end with a 5-minute cool down. During each exercise session, individuals will wear a heart rate monitor rating of perceived exertion will be recorded.

Primary Outcomes

  • Cerebrovascular Insulin Sensitivity (Change from baseline to the end of the intervention at 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-08-03
Completion: 2029-05-31
Eligibility
Age: 55 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Steven K Malin, PhD (PRINCIPAL_INVESTIGATOR) - Rutgers University - New Brunswick
Contact Information
Study Contact:
Steven K Malin, PhD
848-932-7540
steven.malin@rutgers.edu
Emily M Heiston, PhD
848-932-7540
emily.heiston@rutgers.edu
Fei Chen
732-235-5966
chenf2@rwjms.rutgers.edu
Robert Wood Johnson University Hospital Clinical Research Center
Interventions
  • Drug: Intranasal Insulin — Dosage will be 20 IU of INI twice per day (40 IU in total/day). The study will use the Kurve Technology intranasal device, which delivers a 20 second stream of insulin through a nose piece into a nostril, after which the device switches off. The process will then be repeated in the other nostril.
  • Drug: Intranasal Placebo — Saline will be administered twice daily (20 seconds in each nostril) using the Kurve Technology intranasal insulin device.
  • Behavioral: High Intensity Exercise — High intensity exercise will consist of 16 weeks of walking at \~85% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk. The duration of each exercise session will be adjusted based on fitness level so that \~300 kcal will be expended per training session during weeks 1-2, 350 kcal per training session during weeks 3-4, and 400 kcal per training session during weeks 5-16. This usually equals \~60 minutes per session but can vary from person to person. Each session will start with a 5-minute warm-up and end with a 5-minute cool down. During each exercise session, individuals will wear a heart rate monitor rating of perceived exertion will be recorded.
Study Locations (4 sites)
Robert Wood Johnson University Hospital Clinical Research Center, New Brunswick, New Jersey 08091 United States
Institute for Food, Nutrition, and Health, New Brunswick, New Jersey 08901 United States
Rutgers University Loree Gymnasium, New Brunswick, New Jersey 08901 United States
Center for Advanced Human Brain Imaging Research, Piscataway, New Jersey 08854 United States
Eligibility Criteria
Inclusion Criteria: * Male or female 55-80 years old * Type 2 diabetes diagnosis or confirmation HbA1c \>6.5% and fasting glucose \>126 mg/dl * Individuals prescribed metformin, GLP-1 agonists (oral/injectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors \>6 months. * MOCA ≥26 * Body mass index (BMI) ≥25 and ≤40 kg/m2 * Not diagnosed with Type 1 diabetes * Not currently engaged in \<90 min/wk of exercise Exclusion Criteria: * A diagnosis of dementia * Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.) * Intolerance to insulin * Morbidly obese patients (BMI \>40 kg/m2) and lean patients (BMI \<25 kg/m2) * \>2 kg weight change in past 6 months * Participants who have been recently active (\>90 min of moderate/high intensity exercise) * Individuals who are smokers or who have quit smoking (\<2 years) * Hypertriglyceridemia (400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects * Uncontrolled Hypertensive (\>160/100 mmHg) * Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety * Pregnant (as evidenced by positive pregnancy test) or nursing women * Participants with contraindications to participation in an exercise training program * Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol/substance abuse) * History of head trauma or loss of consciousness in last 5 years. * Known contraindications for MR imaging: * History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results. * Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted). * Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies. * Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded. * History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask * Lead/iron tattoos * Claustrophobia (history of significant anxiety in closed places). * Back problem that would prevent the subject from laying still comfortably for up to 90 minutes. * Deafness
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 956
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 40 weeks of continuous administration in study participants with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control on oral antidiabetic medications.A total of 956 participants are planned to be enrolled, including the UBT251 Injection 2 mg group, 4 mg group, 6 mg group, and Semaglutide group,with an approximate study duration of 58 weeks per participant.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: UBT251 Injection 2.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 4.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 6.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: Semaglutide Injection — Semaglutide Injection subcutaneously once weekly

Primary Outcomes

  • HbA1c (Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-09-07
Completion: 2028-02-29
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 956 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Contact Information
Study Contact:
Haiyan Zhang
+86 18998165570
zhanghy@tul.com.cn
Interventions
  • Drug: UBT251 Injection 2.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 4.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 6.0 mg group — UBT251 Injection subcutaneously once weekly
  • Drug: Semaglutide Injection — Semaglutide Injection subcutaneously once weekly
Study Locations (1 sites)
Zhongshan Hospital,Fudan University, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 75 years (inclusive) at the time of signing informed consent, with no restriction on gender; * Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the 2019 World Health Organization (WHO) criteria (Appendix 1), with glycated hemoglobin (HbA1c) ≥7.5% and ≤11.0%; * Participants with inadequate glycemic control despite stable treatment for 3 months prior to screening with 1) metformin; or 2) metformin in combination with sulfonylurea; or 3) metformin in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitor, with the following dosage requirements: Metformin: ≥1500 mg/day or maximum tolerated dose (at least ≥1000 mg/day); Sulfonylurea: half of the maximum daily dose as specified in the package insert or maximum tolerated dose (see Appendix 2 for details); SGLT2 inhibitor: daily dose approved in the package insert (see Appendix 2 for specific products and dosage requirements). * Body mass index (BMI) ≥23.0 kg/m² at screening, with stable body weight for 3 months prior to screening (change \<5%, based on participant's report); * Participants (including their partners) with no plan for pregnancy from screening until 6 months after completion of the study, willing to use contraceptive measures, and with no plan to donate sperm or ova within 6 months after study completion; * Participants who have been fully informed about the study and have voluntarily signed written informed consent. Exclusion Criteria: * Known history of hypersensitivity to the investigational medicinal product or its excipients or other similar active drugs; * Treatment with any of the following medications within 3 months prior to screening: 1. Other antidiabetic medications except background therapy (short-term insulin use ≤14 days for acute conditions is allowed, e.g., perioperative period or hospitalization); 2. Medications that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc. (excluded if cumulative use \<7 days and the end of treatment is \>7 half-lives prior to the first day of screening); 3. Weight-loss medications (including but not limited to orlistat, semaglutide, or other similar prescription or over-the-counter drugs for weight loss). * History or evidence of any of the following diseases: 1. Diagnosis of other types of diabetes: such as Type 1 diabetes mellitus, special types of diabetes (e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, etc.); 2. History of acute or chronic pancreatitis, or pancreatic surgery; 3. History of symptomatic gallbladder disease within 1 year prior to screening (participants who have undergone cholecystectomy \[completed at least 3 months prior to screening\] without long-term complications are excluded); or abdominal ultrasound at screening indicating large gallbladder stones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the investigator comprehensively determines may affect participant safety; 4. Personal or family history (first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); 5. History of hematological disorders that may affect HbA1c test results or increase participant risk (e.g., aplastic anemia, myelodysplastic syndrome, etc.), or any disease causing hemolysis or red blood cell instability (e.g., sickle cell disease, thalassemia, etc.); 6. History of moderate to severe depression or history of severe psychiatric disorders (including but not limited to suicidal ideation or suicide attempt, schizophrenia, bipolar disorder, etc.); 7. History of clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as: 1. Myocardial infarction (MI) or unstable angina; 2. Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention); 3. Congestive heart failure (New York Heart Association \[NYHA\] Class III-IV) (see Appendix 3 for details); 4. Cerebrovascular accident (excluding old lacunar infarction), including but not limited to hemorrhagic or ischemic stroke or transient ischemic attack; 5. Other cardiovascular or cerebrovascular diseases assessed by the investigator as unsuitable for participation in this study; 8. Severe retinal or macular lesions at screening (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.), and the investigator determines that further urgent treatment is required; 9. Severe hypoglycemia (hypoglycemia with severe cognitive impairment requiring other therapeutic measures to assist recovery) or recurrent symptomatic hypoglycemia (≥2 times within 6 months) within 6 months prior to screening; 10. History of acute metabolic complications of diabetes (including but not limited to diabetic ketoacidosis, hyperosmolar hyperglycemic state requiring hospitalization, hyperosmolar coma, lactic acidosis, etc.) or diabetic foot within 6 months prior to screening; 11. Concurrent gastrointestinal emptying disorders (e.g., gastroparesis, pyloric obstruction, intestinal obstruction, etc.) at screening, gastrointestinal diseases assessed by the investigator as increasing risk after administration (e.g., severe active ulcer, inflammatory bowel disease, acute gastroenteritis, uncontrolled gastroesophageal reflux disease, etc.), or history of major gastrointestinal surgery (gastrointestinal polypectomy, appendectomy, cholecystectomy, etc. that have completely recovered and are assessed by the investigator as not affecting study safety are excluded); 12. Major surgery, severe trauma, or severe infection within 1 month prior to screening, assessed by the investigator as unsuitable for participation in this study; 13. History of malignant tumors (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and assessed by the investigator as currently stable); 14. Concurrent other diseases, such as respiratory, urinary, neurological, hematological, immune system diseases, etc., and the investigator considers that they affect participant safety, efficacy evaluation, or compliance. * Screening results showing any of the following abnormal findings: 1. Hepatic or renal impairment: serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥3× upper limit of normal (ULN); serum total bilirubin (TBIL) ≥1.5×ULN; estimated glomerular filtration rate (eGFR) \<45 mL·min-¹·1.73m-² (calculated according to the CKD-EPI 2021 equation, see Appendix 4); 2. Serum calcitonin ≥50 pg/mL (i.e., 50 ng/L); 3. Thyroid dysfunction not controlled with stable drug dosage, or clinically significant abnormalities in thyroid function test results at screening requiring initiation of treatment, or thyroid ultrasound at screening indicating thyroid nodules ≥TI-RADS 4a (or ≥TR4 according to the US classification standard) or assessed by the investigator as possibly requiring biopsy and/or surgery during the study period; 4. Fasting triglycerides ≥5.6 mmol/L; 5. Serum amylase and/or lipase \>2.0×ULN; 6. International normalized ratio (INR) above the upper limit of the normal range; 7. Hemoglobin \<100 g/L; 8. Untreated or poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, based on the mean of 3 blood pressure measurements during the screening period); 9. Clinically significant electrocardiogram (ECG) abnormalities, such as: 1. Second-degree or third-degree atrioventricular block; 2. Long QT syndrome, or QT interval corrected using Fridericia's formula (QTcF) \>470 ms for female participants or \>450 ms for male participants (calculation formula see Appendi
Conditions Metabolic Dysfunction-Associated Steatot...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease locally and globally. MASLD and type 2 diabetes mellitus (T2DM) are closely related with alarmingly high prevalence of MASLD in people with T2DM, along with the escalated risk of adverse clinical outcomes. Our group has reported that around 70% of people with T2DM have increased controlled attenuation parameter (CAP) suggestive of hepatic steatosis and one out of six had advanced liver fibrosis as evidenced by increased liver stiffness measurements (LSM). Despite its prevalence, close relationships and potential consequences, the mechanisms underlying the complex interconnections between MASLD and T2DM are not fully understood. MASLD is associated with a twofold higher risk of developing T2DM, independent of obesity and other common metabolic risk factors. This risk increases with the severity of MASLD, such that patients with more advanced stages of liver fibrosis are at a higher risk of developing T2DM. Moreover, the progression from hepatic steatosis to fibrosis is an important, yet not fully understood, step towards cirrhosis and end-stage liver disease. Identification of clinical predictors and biomarkers to select individuals with MAFLD for close monitoring is pivotal to prevent the sinister outcomes. To date, longitudinal cohorts with paired biobank focused on people with diabetes and comorbid MASLD for investigating the clinical courses and biomarkers for prediction of outcomes are lacking. We hypothesized that Hong Kong Chinese T2DM with comorbid steatotic liver disease have unique clinical courses and special biomarkers for predicting the progression to advanced liver fibrosis. The aims of this study are: 1) establish a prospective cohort of people with T2DM and comorbid steatotic liver disease accompanied with the setting up of a biobank; 2) elucidate the clinical courses and outcomes of Hong Kong Chinese T2DM with comorbid steatotic liver disease; 3) identify potential diagnostic markers of advanced liver fibrosis in people with T2DM and comorbid steatotic liver disease in Hong Kong. The primary outcome measure will be all-cause mortality and secondary outcome measure will be fatal and non-fatal CVD, heart failure, hospitalizations, NT-proBNP levels, and novel diagnostic markers of MASH in people with T2DM comorbid with MASLD.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention (observational study) — There is no intervention involved in this observational study.

Primary Outcomes

  • All-cause mortality (15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-11
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Alice Pik Shan Kong, MD
+852 3505 2648
alicekong@cuhk.edu.hk
Alice Pik Shan Kong, MD
+852 3505 2648
alicekong@cuhk.edu.hk
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Interventions
  • Other: No intervention (observational study) — There is no intervention involved in this observational study.
Study Locations (1 sites)
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital, Hong Kong, New Territories 99977 Hong Kong
Eligibility Criteria
Inclusion Criteria: * T2DM. * Aged ≥ 18 years. * Able and willing to give Informed written consent. Exclusion Criteria: * Type 1 diabetes. * Terminal illness such as malignancy with limited life expectancy. * Any condition, as judged by the investigators, as ineligible to participate in this study.
Conditions Diabetes Mellitus, Type 2, Diabetic Card...
Phase Not Applicable
Enrollment 593
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood. Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D). Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation. Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption. Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy — CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
  • Diagnostic Test: Transthoracic echocardiography — Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
  • Diagnostic Test: Computed tomography coronary artery calcium scoring — Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
  • Diagnostic Test: Cardiopulmonary exercise testing — Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
  • Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) — A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
  • Diagnostic Test: Ambulatory blood pressure monitoring — A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
  • Diagnostic Test: Accelerometer watch — Watch worn to collect free living physical activity data for 7 days.
  • Diagnostic Test: Blood tests — Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.

Primary Outcomes

  • Prevalence of early heart failure in type 2 diabetes (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-10-24
Completion: 2029-10-31
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 593 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leicester
Principal Investigators:
  • Gerry P McCann, MD (PRINCIPAL_INVESTIGATOR) - University of Leicester
Contact Information
Study Contact:
Gerry P McCann, MD
01162583402
gpm12@le.ac.uk
Gaurav S Gulsin, MBChB(Hons)
01162583244
gg149@leicester.ac.uk
Gaurav S Gulsin, MRCP(UK)
University of Leicester
Interventions
  • Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy — CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
  • Diagnostic Test: Transthoracic echocardiography — Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
  • Diagnostic Test: Computed tomography coronary artery calcium scoring — Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
  • Diagnostic Test: Cardiopulmonary exercise testing — Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
  • Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) — A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
Study Locations (1 sites)
University of Leicester, Leicester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥18 and ≤75 years. * Diagnosed with Stable type 2 diabetes (determined by: i) formal diagnosis in GP case records, ii) a record of diagnostic oral glucose tolerance test OR glycated haemoglobin level ≥6.5%). Exclusion Criteria: * Angina pectoris or limiting dyspnoea (\>NYHA II), * Major atherosclerotic disease: Symptomatic CAD, history of myocardial infarction, previous revascularisation, stroke/transient ischaemic attack or symptomatic peripheral vascular disease. * Atrial fibrillation or flutter. * Moderate or severe valvular heart disease. * History of heart failure or cardiomyopathy. * Type 1 diabetes mellitus (T1DM). * Low fasting C-peptide levels suggestive of adult-onset T1DM. * Stage III-V renal disease (estimated glomerular filtration rate ≤30ml/min/1.73m2). * Absolute contraindications to CMR. Importantly, patients with subclinical CAD, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. This will enable us to evaluate the contribution of CAD to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. Similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 3000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study is a post-marketing, multicenter, prospective, observational study designed to evaluate the efficacy and safety of Proline Plus Empagliflozin Tablets in the real-world clinical treatment of type 2 diabetes mellitus. The study does not interfere with routine clinical practice, and Proline Plus Empagliflozin Tablets may be used either as monotherapy or in combination with other therapeutic agents based on actual clinical needs.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • HbA1c <7.0% (at 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-30
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Information
Study Contact:
Bi Yan
86+13655176388
biyan@nju.edu.cn
Ge Zhi Juan
86+18061758651
gzjyunduan@126.com
Shen Hongmei Shen Hongmei, Master Degree Candidate
19837622007
48762111@qq.cn
Xinyang Central Hospital
Interventions
N/A
Study Locations (2 sites)
Xinyang Central Hospital, Xinyang, Henan 464000 China
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: * 1.Age ≥18 years, regardless of gender. 2.Clinically diagnosed with type 2 diabetes mellitus (per the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus \[2020 Edition\]). 3.Deemed suitable by the investigator for treatment with proline-containing gliflozin tablets (Hui You Jing) and being prescribed this medication for the first time. 4.Availability of glycated hemoglobin (HbA1c) test results within 4 weeks prior to enrollment. 5.Voluntary participation with signed informed consent. Exclusion Criteria: \- 1.History of moderate to severe renal impairment (eGFR \<30 mL/min/1.73 m²), end-stage renal disease, or dialysis. 2.Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Severe allergy to gliflozin or any excipient of the study drug. 3.Current or recent (within 1 month) participation in any other clinical trial. 4.Investigator judgment of unsuitability for the study.
Conditions Postoperative Pain
Phase Not Applicable
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to determine the incidence and clinical characteristics of rebound-breakthrough pain after ultrasound-guided brachial plexus block in adult patients with type 2 diabetes mellitus. Adult patients undergoing elective upper-extremity surgery are divided into a type 2 diabetes group and a non-diabetic control group. Baseline clinical data and pain-related outcomes are collected after nerve block. This work may provide evidence for optimizing perioperative pain management for diabetic patients receiving brachial plexus block.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Incidence of postoperative rebound-breakthrough pain (Within 48 hours after brachial plexus block)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-20
Completion: 2026-09-20
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Hospital of Shanxi Medical University
Principal Investigators:
  • Li li Wang (STUDY_DIRECTOR) - Second Hospital of Shanxi Medical University
Contact Information
Study Contact:
Wen bo Wang
+8618636532676
1525565253@qq.com
Zheng Guo
+863513365790
guozheng713@yahoo.com
Second Hospital of Shanxi Medical University
Interventions
N/A
Study Locations (1 sites)
Second Hospital of Shanxi Medical University, Taiyuan, China
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Undergoing elective upper-extremity surgery * Planned for ultrasound-guided brachial plexus block with 0.375% ropivacaine * Able to cooperate with pain assessment and follow-up within 48 hours after block * Written informed consent obtained Exclusion Criteria: * Allergy or contraindication to amide-type local anesthetics * Pre-existing peripheral neuropathy of the affected upper limb * Chronic regular use of opioids before surgery * Coagulopathy or infection at the block puncture site * Cognitive dysfunction unable to complete NRS pain evaluation * Pregnancy or lactation * Incomplete clinical data expected during follow-up